Literature DB >> 19430980

Efficacy and safety of prolonged immunomodulatory treatment with interferon beta.

T L Demina1, N V Khachanova, M V Davydovskaya, N F Popova, E I Gusev.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19430980     DOI： 10.1007/s11055-009-9151-5

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN： 0097-0549


× No keyword cloud information.
  14 in total

1.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Authors:  L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

2.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

3.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

Authors:  B Runmarker; O Andersen
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

4.  PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

Authors: 
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

5.  Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Authors:  L Kappos; A Traboulsee; C Constantinescu; J-P Erälinna; F Forrestal; P Jongen; J Pollard; M Sandberg-Wollheim; C Sindic; B Stubinski; B Uitdehaag; D Li
Journal:  Neurology       Date:  2006-09-26       Impact factor: 9.910

6.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

7.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

Review 8.  The natural history of multiple sclerosis.

Authors:  B G Weinshenker
Journal:  Neurol Clin       Date:  1995-02       Impact factor: 3.806

9.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

10.  Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients.

Authors:  C Confavreux; G Aimard; M Devic
Journal:  Brain       Date:  1980-06       Impact factor: 13.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.